Kezar Life Sciences, Inc. Common Stock
Compare this stock
KZR Stock Report Card
$
37%
Performance
Score:
10/100
KZR returned -90.12% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
Score:
94/100
4 analysts offer 12-month price targets for KZR. Together, they have an average target of 17.5, the most optimistic target put KZR at 21 within 12-months and the most pessimistic has KZR at 14.
Sentiment
Score:
71/100
KZR had a bullish sentiment score of 71.02% across Twitter and StockTwits over the last 12 months. It had an average of 2.88 posts, 0.88 comments, and 0.62 likes per day.
Technicals
Score:
29/100
KZR receives a 28 of 100 based on 14 indicators. 3 are bullish, 9 are bearish.
Earnings
Score:
10/100
KZR has missed earnings 6 times in the last 20 quarters.
Profit
Score:
10/100
Out of the last 20 quarters, KZR has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
Score:
41/100
KZR has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.
Kezar Life Sciences, Inc. Common Stock Summary
Nasdaq / KZR
Healthcare
Biotechnology
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
KZR scored poorly on our reportcard. Here are some similar companies and how they performed.
